ViiV Healthcare to start production of dolutegravir in Russia

8 June 2016

UK-based HIV/AIDS specialist company ViiV Healthcare has announced its intention to launch production of its HIV drug dolutegravir drug in Russia at the facilities of Serdix, the local subsidiary of France’s Laboratoires Servier, according to the company, reports The Pharma Letter’s local correspondent.

According to data from ViiV Healthcare, which is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK) and partnered with Pfizer and Shionogi, the current situation with HIV/AIDS in Russia remains complex. This is reflected by high number of patients with HIV/AIDS diagnosis in Russia, which is estimated at 913,035 people, however, in reality, their number may exceed 1.3 million.

The situation is aggravated by the fact that only about 230,000 people living with HIV in Russia receive the needed therapy. The number of patients which are in need of treatment is large, however the Russian government is experiencing a shortage of funds for the purchase of expensive anti-HIV drugs from abroad.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK